A Phase II Trial of ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma
Phase of Trial: Phase II
Latest Information Update: 24 Sep 2019
Price : $35 *
At a glance
- Drugs Docetaxel (Primary) ; Gemcitabine (Primary) ; Pegargiminase (Primary)
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- 04 Jun 2019 Trial design of the study presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 30 May 2018 According to a Polaris Pharmaceuticals media release, the first patient has been dosed in this phase 2 study.
- 22 May 2018 Planned End Date changed from 9 May 2026 to 9 Feb 2025.